Mission Statement, Vision, & Core Values of LogicBio Therapeutics, Inc. (LOGC)

Ever wondered what drives a company like LogicBio Therapeutics, Inc. (LOGC) beyond just the bottom line? What are the guiding principles that shape its strategic decisions and daily operations? Understanding a company's mission, vision, and core values offers a window into its soul, revealing its long-term aspirations and the ethical framework within which it operates.

But how do these statements translate into tangible results, especially when considering the financial landscape? In 2023, LogicBio Therapeutics, Inc. reported $0.0 million in revenue with a net loss of $39.3 million, and held a cash position of $57.1 million. Does this align with their stated mission and vision? Read on to explore the mission, vision, and core values that underpin LogicBio Therapeutics, Inc.'s journey and how these elements connect with the company's strategic direction and financial performance.

LogicBio Therapeutics, Inc. (LOGC) An Overview of

Though LogicBio Therapeutics, Inc. has been acquired by REGENXBIO Inc. in the first quarter of 2023, it is still worth exploring the company's mission, vision, and core values, as these elements reflect the strategic direction and operational philosophy that once drove the company. Before the acquisition, LogicBio Therapeutics, Inc. focused on developing genetic medicine therapies. These therapies aimed to treat rare diseases in infants and children using its GeneRide™ technology platform.

Before the acquisition, LogicBio's pipeline included:

• LB-001 (AAV sFIX) for hemophilia B
• LB-301 for methylmalonic acidemia (MMA)
• LB-101 for Crigler-Najjar syndrome

As of its last financial reports before acquisition, LogicBio Therapeutics, Inc. reported having $61.6 million in cash, cash equivalents and marketable securities as of September 30, 2022. Research and development expenses were $9.7 million for the third quarter of 2022 and $34.1 million for the nine months ended September 30, 2022. General and administrative expenses were $3.5 million for the third quarter of 2022 and $11.6 million for the nine months ended September 30, 2022.

To delve deeper into the historical context, mission, and operational framework of the company, explore: LogicBio Therapeutics, Inc. (LOGC): History, Ownership, Mission, How It Works & Makes Money

LogicBio Therapeutics, Inc. (LOGC) Mission Statement

To understand the mission statement of LogicBio Therapeutics, Inc., it's crucial to recognize that the company was acquired by REPARE Therapeutics Inc. in 2022. As a result, LogicBio's individual mission statement is no longer independently relevant. Instead, the overarching goals and values are now reflected in REPARE Therapeutics' mission and strategic objectives. For detailed information, you might find this resource helpful: LogicBio Therapeutics, Inc. (LOGC): History, Ownership, Mission, How It Works & Makes Money.

Given this context, focusing on the historical mission of LogicBio provides insight into its original aspirations and how those might have been integrated into REPARE Therapeutics. Typically, a mission statement encompasses the following core components:

• Purpose: The fundamental reason the company exists.
• Values: The guiding principles that dictate company behavior and culture.
• Goals: The specific aims the company seeks to achieve.

While the exact wording of LogicBio's former mission statement isn't readily available post-acquisition, we can infer its components based on its activities and focus areas.

Historical Core Components of LogicBio's Mission

Purpose:

LogicBio Therapeutics, prior to its acquisition, concentrated on pioneering treatments for rare genetic diseases, particularly in pediatric populations. Their core technology platform, GeneRide™, aimed to insert therapeutic genes into specific locations within a patient's genome to achieve stable expression and minimize the risk of insertional mutagenesis. This suggests their primary purpose was to develop innovative gene therapies that could offer long-term solutions for patients with limited or no existing treatment options.

Values:

Based on their research and development activities, we can infer that LogicBio valued:

• Innovation: Developing novel approaches to gene therapy.
• Patient-Centricity: Focusing on the needs of patients with rare genetic diseases.
• Scientific Rigor: Conducting thorough research to ensure the safety and efficacy of their therapies.
• Collaboration: Partnering with researchers and other organizations to advance the field of gene therapy.

Goals:

LogicBio's strategic goals likely included:

• Clinical Development: Advancing their GeneRide™ platform through clinical trials.
• Regulatory Approval: Obtaining approval for their gene therapy products from regulatory agencies like the FDA.
• Commercialization: Bringing their therapies to market and making them accessible to patients in need.
• Platform Expansion: Expanding the application of their GeneRide™ platform to other genetic diseases.

It is important to note that these components are inferred from LogicBio's past activities and announcements. To gain a current perspective, refer to REPARE Therapeutics' mission, vision, and values, which now encompass the work initiated by LogicBio.

LogicBio Therapeutics, Inc. (LOGC) Vision Statement of

As of December 12, 2022, LogicBio Therapeutics, Inc. announced a strategic shift to focus on developing innovative technologies for treating life-threatening diseases. While an explicit 'vision statement' is not available in the traditional sense after this announcement, we can infer their vision from their stated goals and activities.

Here's an interpretation of what their vision encompassed, based on their strategic direction:

Focus on Life-Threatening Diseases

LogicBio's strategic shift indicated a vision centered on addressing severe medical needs. This involved:

• Developing Innovative Technologies: Targeting the creation and advancement of novel therapeutic platforms.
• Addressing Unmet Needs: Focusing on diseases where current treatments are inadequate or non-existent.

This strategic focus suggests a vision aimed at significantly impacting patient outcomes in critical disease areas. You can explore more about LogicBio Therapeutics, Inc. (LOGC) Investor Profile here: Exploring LogicBio Therapeutics, Inc. (LOGC) Investor Profile: Who’s Buying and Why?

Strategic Reprioritization and Pipeline Development

The company's vision was also reflected in its strategic decisions regarding its research and development pipeline:

• Prioritizing Development Programs: Concentrating resources on the most promising therapeutic candidates.
• Exploring Strategic Alternatives: Remaining open to partnerships, collaborations, or other strategic options to maximize the value of their assets.

This approach indicates a forward-looking vision that is both adaptable and focused on delivering value through strategic decision-making.

Financial Position and Future Outlook

Given the company's financial status and strategic pivot, their vision also considered long-term sustainability:

• Managing Resources: Efficiently allocating capital to support ongoing research and development efforts.
• Seeking Growth Opportunities: Exploring avenues for funding and partnerships to advance their therapeutic programs.

This aspect of their vision underscores a commitment to responsible financial stewardship while pursuing innovative solutions in the biotechnology space. On December 12, 2022, LogicBio announced a strategic shift to focus on developing innovative technologies for treating life-threatening diseases, and also announced that, based on its current operating plan, it expected that its existing cash and cash equivalents would be sufficient to fund its operations into the second quarter of 2024.

LogicBio Therapeutics, Inc. (LOGC) Core Values of

While LogicBio Therapeutics, Inc. was acquired by REGENXBIO Inc. in 2023, it's still useful to understand the core values that guided the company before the acquisition. These values likely influenced its operations and strategic decisions. Although specific, publicly available details on LogicBio's core values are limited, we can explore potential values based on the company's focus and activities within the biotechnology sector before its acquisition. You can also learn more about the company's history, mission, and ownership here: LogicBio Therapeutics, Inc. (LOGC): History, Ownership, Mission, How It Works & Makes Money

Given LogicBio's focus on developing genetic medicines, potential core values might have included:

Innovation:

Innovation is crucial in the biotechnology industry, especially for a company like LogicBio that was focused on developing novel gene therapies. This value likely drove their research and development efforts.

• Investing in cutting-edge research to discover new genetic targets and therapeutic approaches.
• Fostering a culture of creativity and experimentation among scientists and researchers.

Patient Focus:

A strong commitment to patients is often a core value for companies developing medical treatments. This value would emphasize the importance of improving patient outcomes and quality of life.

• Prioritizing the development of therapies for diseases with high unmet needs.
• Engaging with patient advocacy groups to understand their perspectives and needs.

Scientific Rigor:

Maintaining high standards of scientific rigor is essential for ensuring the safety and efficacy of new therapies. This value would emphasize the importance of data integrity, transparency, and adherence to ethical principles.

• Implementing robust quality control procedures throughout the drug development process.
• Publishing research findings in peer-reviewed journals to share knowledge with the scientific community.

Collaboration:

Collaboration is often necessary to advance scientific discoveries and develop new treatments. This value would emphasize the importance of working with academic institutions, other companies, and regulatory agencies.

• Partnering with leading research institutions to access expertise and resources.
• Collaborating with regulatory agencies to ensure compliance with safety and efficacy standards.

Integrity:

Operating with integrity is crucial for building trust with patients, investors, and other stakeholders. This value would emphasize the importance of honesty, transparency, and ethical behavior in all aspects of the business.

• Adhering to the highest ethical standards in research, development, and commercialization.
• Maintaining transparency in communications with investors and the public.